Clinical Trial

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research study is studying a targeted therapy as a possible treatment for cancer abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6. The drug involved in this study is: -Abemaciclib
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2017-10-11; most recent amendment 2026-04-24.
Status change: Not Yet Recruiting → Recruiting 2017-11-30
Trial Details
NCT Number NCT03310879
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Eli Lilly and Company
Conditions Cancer
Enrollment 38 participants
Start Date 2017-11-21
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-29